Glioblastoma is currently considered the most common and, unfortunately, also the most aggressive primary brain tumor, with the highest morbidity and mortality rates. The average survival of patients diagnosed with glioblastoma is 14 months, and only 2% of patients survive 3 years after surgery. Based on our clinical experience and knowledge from extensive clinical studies, survival is mainly related to the molecular biological properties of glioblastoma, which are of interest to the general medical community. Our study examined a total of 71 retrospective studies published from 2016 through 2022 and available on PubMed that deal with mutations of selected genes in the pathophysiology of GBM. In conclusion, we can find other mutations within a given gene group that have different effects on the prognosis and quality of survival of a patient with glioblastoma. These mutations, together with the associated mutations of other genes, as well as intratumoral heterogeneity itself, offer enormous potential for further clinical research and possible application in therapeutic practice.

Institute of Molecular and Clinical Pathology and Medical Genetics University Hospital Ostrava 17 listopadu 1790 5 708 00 Ostrava Czech Republic

Medical Faculty University of Ostrava Syllabova 19 703 00 Ostrava Czech Republic

Neurosurgery Clinic University Hospital Ostrava 17 listopadu 1790 5 708 00 Ostrava Czech Republic

Citace poskytuje Crossref.org